Nikolaos Marinakis | Neurogenetics | Best Researcher Award

Posted on by Neuroscientists

Dr. Nikolaos Marinakis | Neurogenetics | Best Researcher Award

Dr. Nikolaos Marinakis,  Laboratory of Medical Genetics, NKUA, Greece.

Dr. Nikolaos M. Marinakis is a highly accomplished Molecular Biologist and Geneticist whose career has been devoted to the diagnosis and molecular analysis of rare genetic disorders. With over a decade of laboratory experience and a strong academic background, he has steadily advanced from early bench research in molecular biology to become a Clinical Laboratory Geneticist and genome analyst. His expertise spans whole exome and whole genome sequencing, variant interpretation, CNV and RNA sequencing analysis, and the clinical application of Next Generation Sequencing. Notably, he has contributed to over 1500 molecular diagnoses in patients with rare diseases and has gained international recognition through the ESHG observership at Radboud University Medical Center. Dr. Marinakis exemplifies scientific excellence, clinical impact, and collaborative innovation in human genetics.

Profile

Google Scholar

 

🎓 Early Academic Pursuits

Dr. Nikolaos M. Marinakis embarked on his academic journey with a strong passion for understanding human biology at a molecular level. He earned his Bachelor’s degree in Molecular Biology and Genetics from the Democritus University of Thrace (DUTH), where he was actively involved in bench research. His undergraduate thesis focused on the functional characterization of NAT1 polymorphisms in the primate Macaca mulatta, offering an early glimpse into his interest in gene function and enzyme activity. This formative research cultivated his technical proficiency in cloning, site-directed mutagenesis, protein purification, and enzymatic assays—skills that would later become instrumental in his advanced academic and clinical endeavors.

🧬 Professional Endeavors in Genetics

Dr. Marinakis has spent more than a decade immersed in both research and clinical laboratories, gaining broad and deep expertise in molecular diagnostics. His professional foundation was laid at the Laboratory of Medical Genetics at St. Sophia’s Children Hospital, affiliated with the National and Kapodistrian University of Athens (NKUA). Here, he progressed from an MSc student to a PhD candidate and eventually to a Scientific Research Associate. His doctoral research was centered on the use of Next Generation Sequencing (NGS) technologies for diagnosing rare genetic disorders, and his project involved bioinformatic evaluation and functional validation of genomic variants. As a current genome analyst, he supervises Clinical Whole Exome Sequencing, routinely interpreting variants in over 1,500 complex diagnostic cases encompassing neurodevelopmental, nephrological, cardiovascular, and ophthalmological diseases.

🔍 Research Contributions and Focus

Dr. Marinakis’s primary research lies at the intersection of clinical genomics and bioinformatics. His scientific focus is on the molecular investigation of rare monogenic disorders, variant classification, and the integration of novel genomic technologies such as long-read sequencing into diagnostic pipelines. He has also contributed to the development and clinical implementation of molecular assays for both postnatal and prenatal diagnostics. His research continues to unravel the genetic underpinnings of syndromes with previously unknown etiologies, enriching the understanding of human genomic complexity. Through RNA sequencing and CNV analysis, he bridges the gap between genotype and phenotype in a clinical context.

🏅 Accolades and Recognition

In recognition of his significant contributions to human genetics, Dr. Marinakis was awarded a competitive observership by the European Society of Human Genetics (ESHG). This prestigious award enabled him to join the Genome Diagnostics unit at the Radboud University Medical Center in the Netherlands under the mentorship of Professor Christian Gilissen. There, he expanded his expertise in whole genome sequencing, variant annotation, structural variation, and advanced bioinformatic pipelines. His growing recognition as a Clinical Laboratory Geneticist (ErCLG-certified) further underscores his professional standing in Europe’s genetics community.

🧠 Impact on Clinical Genomics

Dr. Marinakis has made a measurable impact on translational medicine by bringing genomic science to the bedside. Through his analysis and interpretation of complex NGS datasets, he has helped diagnose hundreds of patients with elusive genetic conditions, directly improving clinical outcomes and enabling personalized treatment strategies. His ability to convert raw genomic data into meaningful clinical insights has made him a key figure in the field of diagnostic genetics in Greece and beyond. His meticulous approach to variant interpretation, especially in challenging or ambiguous cases, continues to guide clinicians in the decision-making process.

🌍 Influence and Collaboration

A committed collaborator and lifelong learner, Dr. Marinakis maintains strong academic and clinical ties with global institutions. His experiences at NKUA and Radboud UMC have equipped him with a broad international outlook on genomics and rare disease research. He actively contributes to cross-border initiatives and research consortiums focused on data sharing, standardization of bioinformatics pipelines, and discovery of novel disease mechanisms. His LinkedIn presence and professional engagement reflect his dedication to connecting with the wider genetics and biomedical community.

🔮 Legacy and Future Contributions

Looking ahead, Dr. Marinakis is poised to lead initiatives that integrate AI-driven genomic interpretation and third-generation sequencing into clinical practice. He aspires to contribute to national and European genomics strategies aimed at early diagnosis, carrier screening, and reproductive planning. By mentoring younger scientists and continuing to publish translational research, he is building a legacy rooted in both scientific rigor and compassionate care. With his strong foundation and forward-thinking vision, Dr. Marinakis represents a dynamic force in the future of precision medicine and rare disease diagnostics.

Publication

  • Title: Phenotype‐driven variant filtration strategy in exome sequencing toward a high diagnostic yield and identification of 85 novel variants in 400 patients with rare Mendelian disorders
    Authors: NM Marinakis, M Svingou, D Veltra, K Kekou, C Sofocleous, FN Tilemis, …
    Year: 2021

 

  • Title: Germline CNV detection through whole-exome sequencing (WES) data analysis enhances resolution of rare genetic diseases
    Authors: FN Tilemis, NM Marinakis, D Veltra, M Svingou, K Kekou, A Mitrakos, …
    Year: 2023

 

  • Title: Case report: a novel synonymous ARPC1B gene mutation causes a syndrome of combined immunodeficiency, asthma, and allergy with significant intrafamilial clinical heterogeneity
    Authors: I Papadatou, N Marinakis, E Botsa, M Tzanoudaki, M Kanariou, I Orfanou, …
    Year: 2021

 

  • Title: The clinical and genetic spectrum of autosomal-recessive TOR1A-related disorders
    Authors: A Saffari, T Lau, H Tajsharghi, EG Karimiani, A Kariminejad, S Efthymiou, …
    Year: 2023

 

  • Title: Expanded phenotypic spectrum of neurodevelopmental and neurodegenerative disorder Bryant-Li-Bhoj syndrome with 38 additional individuals
    Authors: DE Layo-Carris, EE Lubin, AK Sangree, KJ Clark, EL Durham, …
    Year: 2024

 

  • Title: De novo variants in RNF213 are associated with a clinical spectrum ranging from Leigh syndrome to early-onset stroke
    Authors: T Brunet, B Zott, V Lieftüchter, D Lenz, A Schmidt, P Peters, R Kopajtich, …
    Year: 2024

 

  • Title: SDH-deficient renal cell carcinoma: A case report associated with a novel germline mutation
    Authors: V Milionis, D Goutas, D Vlachodimitropoulos, AC Lazaris, I Kyriazis, …
    Year: 2021

 

  • Title: Towards a standard benchmark for variant and gene prioritisation algorithms: PhEval-Phenotypic inference Evaluation framework
    Authors: Y Bridges, V de Souza, KG Cortes, M Haendel, NL Harris, DR Korn, …
    Year: 2024

 

  • Title: Bi-allelic genetic variants in the translational GTPases GTPBP1 and GTPBP2 cause a distinct identical neurodevelopmental syndrome
    Authors: V Salpietro, R Maroofian, MS Zaki, J Wangen, A Ciolfi, S Barresi, …
    Year: 2024

 

  • Title: Combined exome analysis and exome depth assessment achieve a high diagnostic yield in an epilepsy case series, revealing significant genomic heterogeneity and novel mechanisms
    Authors: D Veltra, FN Tilemis, NM Marinakis, M Svingou, A Mitrakos, K Kosma, …
    Year: 2023

 

✅ Conclusion

Dr. Nikolaos M. Marinakis stands out as a distinguished researcher in the field of medical genetics and genomics. His work bridges cutting-edge molecular research with clinical diagnostics, making a direct impact on patient care and the understanding of rare diseases. His technical expertise, international collaborations, and growing leadership in genomic diagnostics reflect both his current achievements and his potential for future contributions to precision medicine. He is a strong candidate for recognition in any academic or professional forum honoring excellence in translational genomics and biomedical research.

Ling-Yan Su | Molecular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Dr. Ling-Yan Su | Molecular Neuroscience | Best Researcher Award

Dr. Ling-Yan Su, Yunnan Agricultural University, China.

Professor Ling-Yan Su is a leading figure in the field of food science and plant physiology, currently serving at the College of Food Science and Technology, Yunnan Agricultural University. With a solid academic foundation from Yunnan University and the Chinese Academy of Sciences, she has built a dynamic career that bridges molecular biology and applied agricultural research. Her pioneering work on melatonin-based pre-harvest treatments has significantly advanced our understanding of natural preservation techniques, especially in prolonging the post-harvest life and quality of fruits like Myrica rubra. Her research focuses on enhancing antioxidant systems, inhibiting spoilage, and activating plant defense pathways through sustainable, low-toxicity treatments.

Profile

Google Scholar

 

🎓 Early Academic Pursuits

Ling-Yan Su’s journey in the biological sciences began with a Bachelor of Science degree from the School of Life Science at Yunnan University (2007–2011). Demonstrating academic curiosity and determination early on, she expanded her horizons through a year-long visiting student program (2010–2011) at the prestigious Kunming Institute of Zoology, affiliated with the Chinese Academy of Sciences. This experience laid the foundation for her doctoral research, which she pursued at the same institute from 2011 to 2017, where she rigorously explored complex biological systems, further solidifying her passion for food science and plant physiology.

🧪 Professional Endeavors in Science

Professor Su’s professional career has been marked by consistent growth across esteemed academic institutions. Following her Ph.D., she joined the Kunming Institute of Zoology as a research assistant, rapidly advancing to the role of associate professor. In 2022, she transitioned to the College of Food Science and Technology at Yunnan Agricultural University, initially as an associate professor before her promotion to full professor within the same year. Her academic trajectory reflects a blend of deep research engagement and an evolving role in shaping food science education and innovation in China.

🌿 Contributions and Research Focus

Professor Su’s groundbreaking work lies at the intersection of plant physiology, post-harvest fruit biology, and food preservation technology. She has made significant contributions to understanding how melatonin, a naturally occurring compound, can be leveraged to extend the post-harvest shelf life of Myrica rubra (Chinese bayberry). Her studies demonstrate that melatonin pre-harvest treatments reduce oxidative stress markers, inhibit microbial decay, and activate the phenylpropanoid pathway, resulting in elevated antioxidant activity. This line of research not only reveals novel mechanisms of fruit preservation but also opens sustainable avenues in post-harvest biology and food safety.

🏅 Accolades and Recognition

While formal awards are not listed, Professor Su’s rapid academic promotions and appointments at prestigious research institutes such as the Chinese Academy of Sciences and Yunnan Agricultural University underscore her recognition within the scientific community. Her work is contributing to a growing body of literature on sustainable food science innovations, earning her esteem among peers and collaborators in the agricultural biotechnology field.

🌱 Impact and Influence

Professor Su’s innovative application of melatonin in fruit preservation has substantial implications for food technology and agricultural practices. Her research directly addresses global concerns such as food spoilage, post-harvest losses, and chemical-free preservation methods. By enhancing natural antioxidant defenses and inhibiting spoilage at a molecular level, her work supports both farmers and consumers in accessing healthier and longer-lasting produce, especially within the context of environmentally conscious food systems.

🔬 Legacy in Food Science

The legacy Professor Su is building centers around translating scientific inquiry into practical solutions for real-world agricultural challenges. Her research is charting a course for future studies in the bio-preservation of fruits and vegetables using natural treatments. As she continues to mentor students and collaborate across disciplines, her influence is extending into the next generation of food scientists and researchers focused on plant biochemistry, post-harvest technology, and sustainable agricultural innovation.

🚀 Future Contributions and Vision

Looking ahead, Professor Ling-Yan Su is poised to further explore how endogenous compounds like melatonin can be applied across various fruits and food crops. Her vision includes broadening the scope of natural food preservation strategies and delving deeper into molecular pathways that regulate plant defense responses. As a respected academic and scientist, her future contributions are expected to shape healthier food systems and deepen scientific understanding of plant–microbe–compound interactions.

Publication

  • Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)
    Authors: DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, …
    Year: 2021

 

  • Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model
    Authors: R Luo, LY Su, G Li, J Yang, Q Liu, LX Yang, DF Zhang, H Zhou, M Xu, …
    Year: 2020

 

  • Melatonin attenuates MPTP-induced neurotoxicity via preventing CDK5-mediated autophagy and SNCA/α-synuclein aggregation
    Authors: LY Su, H Li, L Lv, YM Feng, GD Li, R Luo, HJ Zhou, XG Lei, L Ma, JL Li, …
    Year: 2015

 

  • Decreased mitochondrial DNA copy number in the hippocampus and peripheral blood during opiate addiction is mediated by autophagy and can be salvaged by melatonin
    Authors: YM Feng, YF Jia, LY Su, D Wang, L Lv, L Xu, YG Yao
    Year: 2013

 

  • Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China
    Authors: D Wang, L Xu, L Lv, LY Su, Y Fan, DF Zhang, R Bi, D Yu, W Zhang, XA Li, …
    Year: 2015

 

  • Atg5- and Atg7-dependent autophagy in dopaminergic neurons regulates cellular and behavioral responses to morphine
    Authors: LY Su, R Luo, Q Liu, JR Su, LX Yang, YQ Ding, L Xu, YG Yao
    Year: 2017

 

  • Positive selection rather than relaxation of functional constraint drives the evolution of vision during chicken domestication
    Authors: MS Wang, R Zhang, LY Su, Y Li, MS Peng, HQ Liu, L Zeng, DM Irwin, …
    Year: 2016

 

  • Melatonin alleviates morphine analgesic tolerance in mice by decreasing NLRP3 inflammasome activation
    Authors: Q Liu, LY Su, C Sun, L Jiao, Y Miao, M Xu, R Luo, X Zuo, R Zhou, P Zheng, …
    Year: 2020

 

  • Out of Southern East Asia of the brown rat revealed by large-scale genome sequencing
    Authors: L Zeng, C Ming, Y Li, LY Su, YH Su, NO Otecko, A Dalecky, S Donnellan, …
    Year: 2018

 

  • Moringa oleifera Lam. leaves as new raw food material: A review of its nutritional composition, functional properties, and comprehensive application
    Authors: M Yang, L Tao, XR Kang, ZL Wang, LY Su, LF Li, F Gu, CC Zhao, J Sheng, …
    Year: 2023

 

✅ Conclusion

Professor Su’s academic journey and research contributions exemplify scientific excellence rooted in sustainability and innovation. Her work not only provides practical solutions to post-harvest challenges but also contributes to broader efforts in reducing food waste and promoting natural preservation methods. As she continues to mentor young researchers and expand her studies, Professor Su is well-positioned to leave a lasting impact on food science and agricultural biotechnology. Her career reflects a thoughtful integration of research, application, and forward-looking vision in the quest for healthier and more resilient food systems.

Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Dr. Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Dr.  Liliana Elena Weimer, Center For Global Health Istituto Superiore di Sanita’ Rome, Italy.

Dr. Liliana Elena Weimer is a highly accomplished physician and clinical researcher , where she has risen to the prestigious Level II “First Researcher” position. Her professional focus lies in clinical trials for infectious diseases, particularly HIV and Hepatitis C. She has played a critical role in major national and international research efforts, including collaborations with the U.S. Clinical Trials Group and leadership of the large-scale PITER cohort involving 25,000 HCV patients. She is known not only for her scientific contributions but also for her humanitarian efforts during the COVID-19 emergency. Among her recognitions is the 1st Prize at the 2019 International Congress on Hepatitis C in Seville. Throughout her career, she has exemplified scientific integrity, dedication, and service to public health.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born on December 19, 1965, in Buenos Aires to Italian parents, Dr. Liliana Elena Weimer embraced her dual heritage and committed herself to a life in medicine and research. With Italian citizenship and deep academic determination, she laid the groundwork for her career by studying medicine, ultimately finding her professional home in Italy. Her academic path, though not fully detailed, clearly led her toward a focus on clinical medicine and infectious diseases, with her earliest professional roles marking the beginning of a lifelong engagement in public health and biomedical research. Her intellectual dedication and international roots later became an asset in global research collaborations.

🩺 Professional Endeavors

Dr. Weimer’s distinguished career spans over three decades at the Italian National Institute of Health (ISS), beginning in 1985. Starting as a dedicated clinical physician, she ascended to Level III researcher status by 1990 and continued to grow into higher ranks, culminating in her success in the national Art. 15 competition for the Level II “First Researcher” role in 2022, officially backdated to 2021. Throughout her tenure at ISS, she became a central figure within the Global Health Center in Rome. Known for her tireless commitment, she often described her career not simply as a job but as a “mission,” emphasizing both her personal and professional passion for making a difference in human health.

🧪 Contributions and Research Focus

Specializing in clinical trials, Dr. Weimer has coordinated and participated in numerous groundbreaking studies in HIV and Hepatitis C (HCV). Since the early 1990s, she has collaborated closely with renowned figures such as Prof. Giovanni Rossi, Prof. Stefano Vella, and Prof. Gianni Rezza, contributing to some of the most pivotal HIV antiretroviral therapy trials in history. Her research efforts extended to co-leading and organizing both national and international multicenter clinical trials. Notably, she has been at the forefront of the PITER study, a major nationwide cohort that follows 25,000 patients undergoing HCV treatment—one of the most comprehensive initiatives in Italy in the fight against hepatitis.

🌍 Global Collaborations and Humanitarian Engagement

Her impact extends beyond Italy, thanks to her active involvement with the U.S.-based American Clinical Trials Group on HIV studies. These collaborations have enhanced international understanding and treatment of HIV/AIDS. In addition to her clinical and research commitments, Dr. Weimer also devoted herself to frontline service during the COVID-19 pandemic. Volunteering both with the Civil Protection unit and at Bambino Gesù Children’s Hospital, she demonstrated profound humanitarian values. Her presence during a critical time underscored her belief in serving communities not just from behind a lab desk but also on the ground, directly supporting patients and health systems under strain.

🏅 Accolades and Recognition

Dr. Weimer’s work has been acknowledged at both national and international levels. One of the most prominent recognitions she received was the 1st Prize at the International Congress on Hepatitis C held in Seville in November 2019, a testament to her excellence and influence in the field of infectious disease research. Her achievements are not only measured in accolades but also in the tangible difference her work has made in advancing therapy options and clinical management of chronic viral diseases. Her rise within the ISS and the trust placed in her leadership of major research projects further affirm her standing within the scientific community.

💡 Impact and Influence

Over the course of her extensive career, Dr. Weimer has significantly shaped clinical research strategies in Italy, especially regarding chronic viral infections. Her coordination of thousands of patient cases within structured clinical trials has informed policy decisions and improved treatment protocols nationwide. Her presence at the ISS has also influenced future generations of researchers and clinicians, many of whom benefited from her mentorship, leadership, and example of scientific integrity. Through her rigorous methods and patient-focused approach, she has played a key role in Italy’s standing as a leader in global health research, especially in relation to HIV and HCV.

🔬 Legacy and Future Contributions

Looking forward, Dr. Weimer’s contributions will continue to echo through the fields of virology and clinical medicine. Her involvement in the PITER cohort and other studies has laid down essential groundwork for long-term epidemiological surveillance and patient care strategies. With her appointment as First Researcher, she enters a new chapter of leadership, likely to drive more innovative, patient-centered research initiatives in global health. Her legacy lies not only in her publications or awards but also in the thousands of lives improved by the treatments she helped to test, refine, and implement. The combination of scientific rigor and heartfelt service defines her enduring contribution to modern medicine.

Publication

  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C – TR Morgan, MG Ghany, HY Kim, KK Snow, ML Shiffman, JL De Santo, … – 2010

 

  • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients – SL George, BR Bacon, EM Brunt, KL Mihindukulasuriya, J Hoffmann, … – 2009

 

  • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis – V Saxena, L Nyberg, M Pauly, A Dasgupta, A Nyberg, B Piasecki, … – 2015

 

  • Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy – D Persaud, SC Ray, J Kajdas, A Ahonkhai, GK Siberry, K Ferguson, … – 2007

 

  • Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study – EB Tapper, BR Bacon, MP Curry, DT Dieterich, SL Flamm, LE Guest, … – 2016

 

  • Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with< 50 copies/ml HIV-1 RNA – S Baroncelli, CM Galluzzo, MF Pirillo, MG Mancini, LE Weimer, … – 2009

 

  • Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study – R Mellado-Artigas, LE Mujica, ML Ruiz, BL Ferreyro, F Angriman, E Arruti, … – 2021

 

  • A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients – M Floridia, R Bucciardini, D Ricciardulli, V Fragola, MF Pirillo, LE Weimer, … – 1999

 

  • Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort – LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, … – 2017

 

  • Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER network – LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti, A Gori, A Soria, … – 2017

 

🏁 Conclusion

Dr. Weimer stands as a distinguished figure in the field of global health research, with deep expertise in clinical trials and infectious diseases. Her legacy is marked by landmark contributions to HIV and HCV treatment protocols, influential collaborations, and compassionate public service. Her ongoing work continues to shape public health policy and medical research in Italy and beyond. As she advances in her leadership role at the ISS, her experience, insight, and dedication will remain vital to future innovations in clinical research and global health.

Hao Lai | Clinical Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Prof. Dr. Hao Lai | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Hao Lai, Zhongshan Hospital, Fudan University, China.

Dr. Hao Lai is a distinguished cardiovascular surgeon and researcher, currently serving as Chief Physician at Zhongshan Hospital, Fudan University. With over 20 years of clinical expertise, he specializes in aortic and cardiovascular surgery. His academic achievements include a Ph.D. in Surgery from Fudan University and significant contributions to the study of epigenetic mechanisms in thoracic aortic dissection. As a principal investigator of nationally funded projects and co-author of influential publications, Dr. Lai combines scientific rigor with clinical innovation. He has also played a key role in medical education and device development through industry collaboration.

Profile

Scopus

 

🎓 Early Academic Pursuits

Dr. Hao Lai began his academic journey with a strong foundation in medical sciences, culminating in a Ph.D. in Surgery from the prestigious Fudan University. His early academic pursuits were marked by a deep interest in cardiovascular physiology and surgical intervention, which later matured into a specialized focus on aortic diseases. His time as a doctoral candidate not only equipped him with rigorous scientific training but also ignited his lifelong commitment to solving complex clinical problems through research.

🏥 Professional Endeavors

Currently serving as Chief Physician at Zhongshan Hospital, Fudan University, Dr. Hao Lai has accumulated over two decades of extensive clinical experience in cardiovascular and aortic surgery. His professional trajectory reflects a seamless integration of surgical excellence with academic leadership. At Zhongshan Hospital, a leading institution in China, he has spearheaded several clinical programs aimed at enhancing patient outcomes in cases of thoracic aortic dissection and other high-risk cardiovascular conditions.

🔬 Contributions and Research Focus

Dr. Lai’s research centers around the epigenetic mechanisms underlying thoracic aortic dissection, with a particular focus on histone modification and DNA methylation. He is the Principal Investigator of a major research project funded by the National Natural Science Foundation of China, which explores the role of H3K36me3 histone modification and DNMT3B-mediated gene body methylation in the pathogenesis of aortic dissection. His scientific efforts bridge molecular pathology with clinical implications, offering new perspectives on the diagnosis and treatment of life-threatening vascular disorders.

🏆 Accolades and Recognition

A respected voice in cardiovascular medicine, Dr. Hao Lai has co-authored numerous influential articles in high-impact journals such as Cardiovascular Research and Advanced Science. His h-index of 18, as listed on Scopus, reflects his consistent scholarly output and the wide academic acknowledgment of his work. In addition, his authorship of the textbook Practical Surgery (3rd Edition), published by People’s Medical Publishing House, stands as a testament to his educational contributions to the next generation of Chinese surgeons.

🧪 Impact and Innovation

Dr. Lai’s research has made a tangible impact on the understanding and treatment of aortic diseases. His investigation into the epigenetic regulation of vascular pathology has opened new avenues for targeted therapies. Moreover, his collaboration with MicroPort Endovascular MedTech demonstrates his commitment to translating research findings into real-world applications, particularly in the development and refinement of endovascular surgical devices.

🌍 Influence and Collaboration

Beyond his direct research and surgical contributions, Dr. Lai’s influence extends into collaborative domains, both nationally and internationally. His leadership in high-level research grants, clinical trials, and industrial partnerships positions him as a central figure in the evolving landscape of cardiovascular surgery. His collaborative spirit fosters innovation and promotes cross-disciplinary dialogue, essential in today’s complex medical research environment.

🔮 Legacy and Future Contributions

As Dr. Hao Lai continues his distinguished career, his legacy is being shaped not only by his surgical accomplishments but also by his contributions to medical science. His ongoing projects are likely to further clarify the molecular landscape of aortic diseases and inspire new therapeutic strategies. Looking ahead, Dr. Lai is poised to remain at the forefront of cardiovascular innovation, committed to improving patient care through a synthesis of research, education, and clinical practice.

Publication

 

Title: Prevalence and predictors of left atrial thrombus in patients with rheumatic atrial fibrillation undergoing cardiac surgery: a cross-sectional study
Authors: J. Cui, Y. Zhang, Y. Wang, Q. Ji, C. Wang
Year: 2025


Title: A novel open-vascular single-branched stent graft in total arch repair of type A aortic dissection one-year results of a prospective multicenter randomized controlled study
Authors: J. Gu, W. Zhang, L. Kang, H. Lai, C. Wang
Year: 2025


Title: Fibroblast Activation Protein Acts as a Biomarker for Monitoring ECM Remodeling During Aortic Aneurysm via 68Ga-FAPI-04 PET Imaging
Authors: C. Hu, H. Tan, Y. Zhang, X. Chen, L. Wang
Year: 2025


Title: Mitochondrial NAD+ deficiency in vascular smooth muscle impairs collagen III turnover to trigger thoracic and abdominal aortic aneurysm
Authors: J. Zhang, Y. Tang, S. Zhang, K. Zhu, W. Zhang
Year: 2025


Title: Correcting mitochondrial loss mitigates NOTCH1-related aortopathy in mice
Authors: Y. Tang, J. Zhang, Y. Fang, Y. Xu, W. Zhang
Year: 2025


Title: Exploration of 68Ga-FAPI-04 PET/MR in Chronic Type B Aortic Dissection
Authors: C. Hu, Y. Zhang, S. Qiu, H. Shi, L. Wang
Year: 2025


Title: Effects of postoperative glucocorticoids on mitigation of organ dysfunction in patients with type A aortic dissection: A randomized controlled trial
Authors: M. Luo, J. Luo, X. Xu, G. Tu, Z. Luo
Year: 2024


Title: Therapeutic results of three-dimensional aortic valve anatomic repair for regurgitant bicuspid aortic valve
Authors: J. Li, C. Wang, Z. Zuo, W. Ding, T. Hong
Year: 2024


Title: 68Ga-FAPI-04 Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Ascending Aortic Aneurysm
Authors: C. Hu, H. Tan, Y. Zhang, H. Lai, L. Wang
Year: 2024


Title: Sex-based outcomes after thoracic endovascular aortic repair: A systematic review and meta-analysis
Authors: Y. Zhang, Y. Zhang, Y. Wang, L. Wang, Q. Ji
Year: 2025

✅ Conclusion

Dr. Hao Lai’s career represents a powerful blend of surgical precision, scientific insight, and academic leadership. His work has advanced the understanding of aortic diseases at the molecular level while improving surgical outcomes for patients. As he continues to mentor, innovate, and lead research at the intersection of epigenetics and cardiovascular pathology, Dr. Lai’s contributions are set to leave a lasting legacy in both clinical practice and medical science.

 

 

Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Prof. Shilin Luo | Neurogenetics and Molecular Neuroscience | Best Researcher Award

Prof. Shilin Luo, Xiangya Hospital, Central South University, China.

Dr. Shilin Luo is a leading expert in neuropharmacology and medicinal chemistry, with a strong academic background in traditional Chinese medicine and modern pharmacology. His research focuses on the pathogenesis of neurodegenerative diseases and the development of innovative drug therapies. Through his work at Xiangya Hospital, Central South University, and previous research at Emory University, he has made significant contributions to understanding neurological disorders. His studies on animal models and risk genes have paved the way for novel treatment strategies, earning him international recognition.

Profile

Scopus

Orcid

 

🎓 Early Academic Pursuits

Dr. Shilin Luo’s journey into the world of medical science began with a deep-rooted passion for understanding the complexities of neurological diseases. He earned his Bachelor’s degree in Chinese Materia Medica from Shenyang Pharmaceutical University, where he developed a strong foundation in traditional Chinese medicine and pharmacology. With an insatiable thirst for knowledge, he further pursued a Ph.D. in Medicinal Chemistry at China Pharmaceutical University, specializing in the research of active ingredients in natural products. Under the mentorship of Prof. Wencai Ye, a distinguished scholar, Dr. Luo honed his expertise in medicinal chemistry, paving the way for groundbreaking discoveries in neuropharmacology.

👨‍🎓 Professional Endeavors

To deepen his expertise, Dr. Luo embarked on postdoctoral research at Emory University’s School of Medicine in the Department of Pathology and Laboratory Medicine. Working under the esteemed Prof. Keqiang Ye, he focused on neurobiology and neuropharmacology, contributing significantly to the understanding of neurodegenerative diseases. His research provided novel insights into the molecular mechanisms underlying neurological disorders, positioning him as a leading figure in the field. He later took on a pivotal role as a professor in the Department of Neurology at Xiangya Hospital, Central South University, where he continues to mentor young scientists and advance medical research.

🧪 Contributions and Research Focus

Dr. Luo’s research is primarily dedicated to uncovering the pathogenesis of neurodegenerative diseases and developing therapeutic interventions. His work in animal models of pathogenic and risk genes for neurological disorders has been instrumental in identifying potential drug targets. By integrating traditional Chinese medicine with modern pharmacology, he has contributed to the development of innovative neuroprotective agents. His studies on the molecular mechanisms of neuronal degeneration have led to promising advancements in combating conditions such as Alzheimer’s and Parkinson’s disease.

🏆 Accolades and Recognition

Throughout his career, Dr. Luo has been widely recognized for his groundbreaking contributions to neuropharmacology. His research has been published in high-impact scientific journals, earning him international acclaim. His dedication to scientific excellence has garnered prestigious awards, and he is frequently invited to deliver keynote lectures at global conferences. His work continues to inspire fellow researchers, solidifying his reputation as a distinguished scientist in neurological drug development.

🏰 Impact and Influence

Dr. Luo’s impact extends beyond the laboratory, as he actively contributes to the medical community through mentorship and collaboration. His efforts in integrating traditional Chinese medicinal principles with cutting-edge pharmacological approaches have opened new avenues for drug discovery. His research findings have not only influenced academic discourse but have also laid the groundwork for potential clinical applications, bringing hope to patients suffering from neurodegenerative diseases.

⚛️ Legacy and Future Contributions

As a visionary scientist, Dr. Luo continues to push the boundaries of neurological research. His commitment to translational medicine aims to bridge the gap between laboratory discoveries and clinical applications. By fostering interdisciplinary collaborations and mentoring the next generation of researchers, he is shaping the future of neuropharmacology.

 

Publication

  • Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
    Authors: Yujie Zhang, Jie Chen, Yanru Li, Bin Jiao, Shilin Luo
    Year: 2025

 

  • The role of the probiotic Akkermansia muciniphila in brain functions: insights underpinning therapeutic potential
    Authors: Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
    Year: 2023

 

  • Nonviral delivery systems for antisense oligonucleotide therapeutics
    Authors: Si Huang, Xin-Yan Hao, Yong-Jiang Li, Jun‑Yong Wu, Da-Xiong Xiang, Shilin Luo
    Year: 2022

 

  • The Microglial membrane receptor TREM2 mediates exosome secretion to promote phagocytosis of amyloid‐β by microglia
    Authors: Si Huang, Xiaoli Liao, Junyong Wu, Xiaojie Zhang, Yamin Li, Daxiong Xiang, Shilin Luo
    Year: 2022

 

  • Correction: Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine
    Authors: Not explicitly listed
    Year: 2021

 

  • Polygonatum sibiricum Polysaccharides Protect against MPP‐Induced Neurotoxicity via the Akt/mTOR and Nrf2 Pathways
    Authors: Si Huang, Haiyan Yuan, Wenqun Li, Xinyi Liu, Xiaojie Zhang, Daxiong Xiang, Shilin Luo, Guodong Zhang
    Year: 2021

 

  • Bushen-Tiansui Formula Improves Cognitive Functions in an Aβ1–42 Fibril-Infused Rat Model of Alzheimer’s Disease
    Authors: Chenxia Sheng, Panpan Xu, Xinyi Liu, Weijun Peng, Daxiong Xiang, Shilin Luo
    Year: 2020

 

  • Osteogenesis activity of isocoumarin a through the activation of the PI3K-Akt/Erk cascade-activated BMP/RUNX2 signaling pathway
    Authors: Not explicitly listed
    Year: 2019

 

  • Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson’s Disease
    Authors: Shilin Luo, Seong Su Kang, Zhi-Hao Wang, Xia Liu, Julia X Day, Zhiping Wu, Junmin Peng, Daxiong Xiang, Wolfdieter Springer, Keqiang Ye
    Year: 2019

 

  • Puerarin-loaded PEG-PE micelles with enhanced anti-apoptotic effect and better pharmacokinetic profile
    Authors: Not explicitly listed
    Year: 2018

 

Conclusion

Dr. Luo’s unwavering dedication to neurological research continues to shape the future of neuropharmacology. His innovative approach, combining traditional medicinal insights with modern scientific advancements, has the potential to revolutionize drug development for neurodegenerative diseases. As a mentor, researcher, and pioneer in his field, his contributions will leave a lasting impact on both academia and clinical medicine, offering hope for more effective treatments in the years to come.